We are live on
!
Find out more
GFM
GF Fund Management Portfolio holdings
AUM
$5.98B
1-Year Est. Return
80.99%
This Fund
S&P 500
This Quarter
Est. Return
+7.58%
1 Year Est. Return
+80.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.62B
AUM Growth
–
Cap. Flow
+$4.56B
Cap. Flow
% of AUM
98.7%
Top 10 Holdings %
Top 10 Hldgs %
48.03%
Holding
637
New
637
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$400M |
| 2 |
Apple
AAPL
|
+$352M |
| 3 |
Microsoft
MSFT
|
+$326M |
| 4 |
Amazon
AMZN
|
+$218M |
| 5 |
Meta Platforms (Facebook)
META
|
+$195M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 45.41% |
| 2 | Consumer Discretionary | 17.29% |
| 3 | Communication Services | 14.35% |
| 4 | Healthcare | 6.6% |
| 5 | Consumer Staples | 4.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
551
Cartesian Therapeutics
RNAC
$218M
| $9.56K | ﹤0.01% |
+534
| New | +$10.8K |
|
552
UroGen Pharma
URGN
$1.97B
| $9.44K | ﹤0.01% |
+886
| New | +$10.6K |
|
553
HUTCHMED
HCM
$1.96B
| $9.38K | ﹤0.01% |
+651
| New | +$11.6K |
|
554
Allogene Therapeutics
ALLO
$625M
| $9.38K | ﹤0.01% |
+4,403
| New | +$10.9K |
|
555
Zevra Therapeutics
ZVRA
$578M
| $9.35K | ﹤0.01% |
+1,121
| New | +$9.57K |
|
556
Alpha Teknova
TKNO
$266M
| $9.34K | ﹤0.01% |
+1,119
| New | +$7.79K |
|
|
BFS
557
Saul Centers
BFS
$858M
| $9.27K | ﹤0.01% |
+239
| New | +$9.58K |
|
558
MaxCyte
MXCT
$108M
| $9.21K | ﹤0.01% |
+2,215
| New | +$8.37K |
|
|
ESPR
559
DELISTED
Esperion Therapeutics
ESPR
| $9.1K | ﹤0.01% |
+4,137
| New | +$9.65K |
|
560
SIGA Technologies
SIGA
$240M
| $9.01K | ﹤0.01% |
+1,499
| New | +$10K |
|
561
OmniAb
OABI
$283M
| $8.99K | ﹤0.01% |
+2,541
| New | +$10.1K |
|
562
Phibro Animal Health
PAHC
$1.5B
| $8.97K | ﹤0.01% |
+427
| New | +$9.88K |
|
563
Monte Rosa Therapeutics
GLUE
$1.82B
| $8.95K | ﹤0.01% |
+1,290
| New | +$9.68K |
|
|
UHT
564
Universal Health Realty Income Trust
UHT
$621M
| $8.82K | ﹤0.01% |
+237
| New | +$9.65K |
|
|
XRN
565
Chiron Real Estate Inc
XRN
$535M
| $8.68K | ﹤0.01% |
+225
| New | +$9.96K |
|
|
KALV
566
DELISTED
KalVista Pharmaceuticals
KALV
| $8.66K | ﹤0.01% |
+1,023
| New | +$10.6K |
|
567
Aura Biosciences
AURA
$725M
| $8.62K | ﹤0.01% |
+1,049
| New | +$9.87K |
|
568
Personalis
PSNL
$1.25B
| $8.57K | ﹤0.01% |
+1,483
| New | +$6.84K |
|
569
AnaptysBio
ANAB
$1.54B
| $8.46K | ﹤0.01% |
+639
| New | +$15.5K |
|
|
OLP
570
One Liberty Properties
OLP
$542M
| $8.39K | ﹤0.01% |
+308
| New | +$8.62K |
|
|
ALX
571
Alexander's
ALX
$1.36B
| $8.2K | ﹤0.01% |
+41
| New | +$9.07K |
|
572
Codexis
CDXS
$158M
| $8.15K | ﹤0.01% |
+1,709
| New | +$7.04K |
|
|
LKFT
573
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
| $8.06K | ﹤0.01% |
+293
| New | +$8.17K |
|
574
Regenxbio
RGNX
$616M
| $8.04K | ﹤0.01% |
+1,040
| New | +$9.77K |
|
|
CLDT
575
Chatham Lodging
CLDT
$632M
| $7.89K | ﹤0.01% |
+882
| New | +$7.82K |
|
Similar funds
CM
BP
AAM
CAG
WHRC
RCG
AL
CGPCS
GF Fund Management's Q4 2024 Portfolio in Review
Q4 2024 is the first quarter with a 13F filing on record for GF Fund Management, which disclosed 637 positions worth $4.62B. Its ten largest holdings account for 48% of the portfolio.
Its largest position is NVIDIA: 2,904,119 shares worth $390M.
By sector, the portfolio is most concentrated in Technology at 45% of assets, followed by Consumer Discretionary and Communication Services.
- GF Fund Management's largest Q4 2024 buy was NVIDIA: 2,904,119 shares worth $390M.
- GF Fund Management's ten largest holdings make up 48% of its $4.62B portfolio in Q4 2024.
- GF Fund Management disclosed 637 positions in Q4 2024, its first 13F filing on record.
Based on GF Fund Management's 13F filing for Q4 2024, filed 19 Feb 2025.